Based on findings from a 17-patient study, a novel breast-specific stereotactic body radiotherapy (SBRT) device known as GammaPod has been approved by the FDA as a treatment for patients with early breast cancer.<br /> <br />
Based on findings from a 17-patient study, a novel breast-specific stereotactic body radiotherapy (SBRT) device known as GammaPod has been approved by the FDA as a treatment for patients with early breast cancer.
In the small clinical trial, GammaPod was effectively used to deliver a single "boost" radiation dose of 8 Gy directly to the tumor, while only eliciting grade 1 adverse events (AEs). The system uses a vacuum-assisted breast cup guided by a CT simulator with 1 mm slice thickness to immobilize the breast, which ensures the accurate delivery of radiation to the tumor.
“With today’s clearance, patients will have access to a treatment option that provides greater accuracy in delivering radiation therapy to breast tumors while saving surrounding breast tissue,” Robert Ochs, PhD, acting deputy director for radiological health in the Office of In Vitro Diagnostics and Radiological Health in the FDA’s Center for Devices and Radiological Health, said in a statement.
The pivotal trial enrolled women aged 60 and older with stage 1 or 2 invasive breast cancer following breast conserving surgery with planned tangential radiation therapy (RT). Following the 8 Gy boost, patients were treated with whole breast irradiation with either a hypofractionated dose of 40 Gy in 15 fractions or 50 Gy in 25 conventional fractions.
Tumor bed volume ranged from 2.86 cc to 20.38cc and the planned target volume (PTV) with 10 mm expansion from the gross target volume (GTV) ranged from 21.69 cc to 89.56 cc. The time needed from CT imaging to completion of treatment was approximately 1 hour, with the actual treatment time being 17 to 29 minutes.
Of the planned 17 patients, signed consent forms were available for 13 patients at the time of a presentation at the 36th ESTRO Congress. Of the 13 patients, 12 successfully completed the treatment protocol. Ten patients received an accurate boost dose of radiation using the system, which met the criteria for the primary endpoint which dictated an acceptable dose for 6 of 8 patients or 13 of 17. One patient with a deep seeded tumor bed received a larger-than-prescribed dose and another had inadequate coverage of the PTV.
Following the boost treatment, one patient developed superficial skin blistering prior to the start of whole breast irradiation. The blistering was seen around a silicone filler. Researchers noted that the blisters were not associated with pain and resolved spontaneously without intervention. The overall AEs for the boost and whole breast irradiation portions of the study were fatigue (n = 7), dermatitis (n = 6), hyperpigmentation (n = 2), breast pain (n = 2), and limb edema (n = 1).
A geometric reproducibility study, also presented at ESTRO, looked at 24 patients with surgical clips in their breast using a CT scan before placement of the GammaPod system and a second 30 minutes after to ensure placement. These findings confirmed the systems' ability to immobilize the breast. The reproducibility for 45 available clips in 11 patients was 1.13 mm (± 0.87).
Studies looking at the GammaPod system were conducted at the University of Maryland School of Medicine, which is where the device was invented. The pivotal trial was cleared and began enrolling patients in 2015.
“The GammaPod system has the potential to change how radiation therapy is delivered for early stage breast cancer patients. It will shorten treatment time allowing patients a faster recovery," principal investigator Elizabeth M. Nichols, MD, assistant professor of radiation oncology and clinical director of the Department of Radiation Oncology at the University of Maryland School of Medicine, toldTargetedOncology.
"The GammaPod system delivers highly targeted radiation therapy to the breast while minimizing radiation dose to the heart, lungs, and surrounding normal breast tissue, which we hope will also result in fewer long term side effects and improved cosmetic outcomes for women,” said Nichols, who is also a radiation oncologist at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center.
The device was approved under the 510(k) premarket notification pathway. Xcision Medical Systems developed and will market GammaPod. The company was launched out of the University of Maryland following a $3.5 million SBIR grant from the National Institutes of Health.
Feigenberg S, Nichols E, Mutaf Y, et al. Initial Clinical Experience with a Noninvasive Breast Stereotactic Radiotherapy Device: the GammaPod. Presented at: 26th ESTRO Congress; May 5-9, 2017; Vienna, Austria. Abstract EP-1183.